Unique catalytic activities and scaffolding of p21 activated kinase-1 in cardiovascular signaling by Yunbo Ke et al.
“fphar-04-00116” — 2013/9/25 — 21:07 — page 1 — #1
REVIEW ARTICLE
published: 27 September 2013
doi: 10.3389/fphar.2013.00116
Unique catalytic activities and scaffolding of p21 activated
kinase-1 in cardiovascular signaling
Yunbo Ke1,2*, Ming Lei3, XinWang4 and R. John Solaro1,2
1 Department of Physiology and Biophysics, University of Illinois at Chicago, Chicago, IL, USA
2 Center for Cardiovascular Research, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA
3 Faculty of Medicine and Human Sciences, Institute of Cardiovascular Sciences, University of Manchester, Manchester, UK
4 Faculty of Life Sciences, Manchester Academic Health Sciences Center, University of Manchester, Manchester, UK
Edited by:
Koichi Baba, Osaka University, Japan
Reviewed by:
Philippe Rondard, Centre National de
la Recherche Scientiﬁque, Institut
National de la Santé et de la
Recherche Médicale, France
Waldiceu A. Verri, Universidade
Estadual de Londrina, Brazil
*Correspondence:
Yunbo Ke, Department of Physiology
and Biophysics, University of Illinois at
Chicago, 835 South Wolcott Avenue,
M/C 901, Chicago, IL 60612-7342,
USA; Center for Cardiovascular
Research, College of Medicine,
University of Illinois at Chicago, 835
South Wolcott Avenue, M/C 901,
Chicago, IL 60612-7342, USA
e-mail: yke@uic.edu
P21 activated kinase-1 (Pak1) has diverse functions in mammalian cells. Although a large
number of phosphoproteins have been designated as Pak1 substrates from in vitro studies,
emerging evidence has indicated that Pak1 may function as a signaling molecule through
a unique molecular mechanism – scaffolding. By scaffolding, Pak1 delivers signals through
an auto-phosphorylation-induced conformational change without transfer of a phosphate
group to its immediate downstreameffector(s). Herewe reviewevidence for this regulatory
mechanism based on structural and functional studies of Pak1 in different cell types and
research models as well as in vitro biochemical assays.We also discuss the implications of
Pak1 scaffolding in disease-related signaling processes and the potential in cardiovascular
drug development.
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INTRODUCTION
In the early 1990s, studies reported by Hall and his colleagues
demonstrated signiﬁcant cytoskeletal reorganization induced by
Rho family small GTPases including RhoA, Cdc42 and Rac1 in
mammalian cells (Paterson et al., 1990; Hall, 1992; Ridley et al.,
1992; Nobes and Hall, 1995). These studies, which revealed
dramatic and fascinating cytoskeletal phenotypes, such as for-
mation (or loss) of stress ﬁbers, induction of lamellipodia and
ﬁlapodia, generated strong enthusiasm to understand the signal-
ing pathways and molecular mechanisms responsible for the cell
remodeling. The identiﬁcation of p21 activated kinase-1 (Pak1)
activation by Cdc42 and Rac1 has provided an exciting clue link-
ing the activity of small G proteins to protein phosphorylation,
a common post-translational modiﬁcation regulating virtually
all of the major physiological processes. Indeed, an increasing
number of phosphoproteins had been claimed as substrates for
Paks ever since. Obviously, validation of authentic substrates
for Pak requires evidence beyond in vitro assays. For instance,
Pak1 was found to phosphorylate both myosin regulatory light
chain and myosin light chain kinase (MLCK) predictably result-
ing in both an increase and a decrease of myosin II activity
(Sanders et al., 1999; Goeckeler et al., 2000; Zeng et al., 2000),
which may not co-exist in vivo. And additional complexity in
understanding Pak1 function in vivo is that mouse models null
for Pak1 expression demonstrate phenotypes similar to wild-type
mice unless subjected to stresses (Liu et al., 2011; Taglieri et al.,
2011).
p21 activated kinase-1 was discovered in rat brain by protein
overlay assay as a Cdc42/Rac1 binding partner (Manser et al.,
1994). Pak1 and Cdc42/Rac1 induced the same cytoskeletal and
morphological changes in mammalian cells (Kozma et al., 1995;
Manser et al., 1997; Sells et al., 1997) supporting the hypotheses
that Pak1 conveys messages from the small GTPases in signal-
ing cascades. It is evident that understanding Pak1 function in
vivo requires determination of the native substrates, which may
serve as immediate downstream effectors for Pak. Unexpect-
edly, the search for “physiological” substrates of Pak has been
formidable.
It is well accepted that a protein kinase functions through trans-
fer of phosphate group(s) to its downstream target(s). This has
been seen in numerous protein kinases as with MLCK, whose
name and function is primarily deﬁned by its obligatory protein
substrate – myosin regulatory light chain (MLC20). Likewise it
would seem important with regard to understanding Pak1 control
mechanisms, to know its physiological substrate(s). Yet studies
with Pak1 mutants cast doubt on the role of phosphorylation
of downstream targets as a prominent Pak1 signaling mecha-
nism. These studies demonstrated that kinase dead mutants of
Pak1 retained the ability to enhance formation of lamellipodia
(Frost et al., 1998) and neurite outgrowth (Daniels et al., 1998;
Obermeier et al., 1998). The phenotypes were expected to be stim-
ulated by Pak1 activation as active Cdc42/Rac1 and Pak1 induce
the same morphological changes. Frost et al. (1998) were the ﬁrst
to use the term “scaffolding” to describe the kinase-independent
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activities of Pak1 regulation of cytoskeletal reorganization. Scaf-
folding may also be induced by auto-phosphorylation of Pak1
as discussed below. In signal transduction, it is a commonly-
used scheme of activation as seen in β-arrestin-mediated signaling
(Pierce et al., 2001; Tohgo et al., 2002) and in Ca2+ triggered sig-
nal transduction from troponins to tropomyosin (Parmacek and
Solaro, 2004). Is it possible that a protein kinase carries out signal
transduction without phosphorylating its downstream target? To
address this question, we discuss Pak1 structure and its mode of
activation.
STRUCTURE AND ACTIVATION MECHANISM
Pak family serine/threonine protein kinases have six members
divided intro group I and group II Paks. Interestingly, although
Pak1 and Pak4 belong to two different groups and are less homol-
ogous to each other, compared with members in the same groups
(Jaffer and Chernoff, 2002), they produce the same cytoskeletal
changes in mammalian cells (Sells et al., 1997; Abo et al., 1998). It
remains unclear whether Pak1 and Pak4 employ the same molec-
ular strategy to produce the cytoskeletal reorganization. Group
I Paks differ from other non-Pak family protein kinases by a
combination of three structural features: a motif-rich regulatory
N-terminal half, which interacts not only with different cellular
partners, but also extensively with the catalytic domain of Paks;
multiple auto-phosphorylation sites mostly clustered in the N-
terminal half, which contribute to both kinase activation and
translocation (Bokoch, 2003); and formation of an antiparallel
homodimer, which integrates the ﬁrst two traits and provides the
structural basis for both auto-inhibition and activation (Lei et al.,
2000; Bokoch, 2003; Figure 1).
Upon activation by upstream signals, accelerated auto-
phosphorylation of Pak1 occurs at multiple sites (Manser et al.,
1997; Zhao et al., 1998). The catalytic domain of Pak1 shares
more than 92% homology with Pak2 and Pak3 (Jaffer and Cher-
noff, 2002). Dimerization places the activation loop from one
Pak1 monomer in the vicinity of the catalytic cleft of the other
monomer. In an auto-inhibitory mode, a segment in the auto-
inhibitory domain (AID) displaces the activation loop away from
key amino acids that carry out the kinase reaction and prevent
phosphorylation of T423 in the loop. This inhibition is released by
Cdc42 andRac1when they bind to the p21 binding domain (PBD)
that is upstream of and overlaps with the AID (Wang et al., 2011a;
Figure 1B). Two auto-phosphorylations in theAID also contribute
to kinase activation (Chong et al., 2001; Lei et al., 2005). The Pak1
dimer is a structure that restricts accessibility of a protein substrate
to the catalytic cleft (Lei et al., 2000, 2005). Although it is generally
accepted that Pak homodimer breaks and separates when stimu-
lated by Cdc42 and Rac1 (Parrini et al., 2002), NMR studies on
Pak2 appear not to support this conclusion. In contrast, phospho-
rylation of Pak2 in the kinase domain promotes dimer formation
in solution (Pirruccello et al., 2006).
Currently, most evidence indicates that Pak1 auto-
phosphorylation occurs through an inter-molecular mechanism
consisting of auto-phosphorylation between two Pak1 monomers
(King et al., 2000; Parrini et al., 2002). Therefore, Pak1 must
have intrinsic capacity to maintain a dynamic dimer structure
FIGURE 1 | (A) p21 activated kinase-1 is divided into N-termial and C-terminal
halves. The N-terminal half contains p21 binding domain (PBD) followed by a
kinase inhibitory domain which overlap with each other. The proline rich
motifs interact with different cellular proteins including Nck, Grb2, and Pix,
etc. Most of the motifs contain or are followed by auto-phosphorylation sites.
T423 is the only auto-phosphosphorylation site in the catalytic domain which
lies in the activation loop. (B) Activation of Pak1 by Cdc42/Rac1. Pak1 forms a
homodimer, an auto-inhibitory conﬁguration. The activation loop is dislocated
from the catalytic center of Pak1 by autoinhibitory domain in inhibitory switch
domain (IS, inhibitory switch).When Cdc42 or Rac1 binds to PBD domain,
the IS is displaced from its inhibitory position and auto-phosphorylation on
activation loop occurs.
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well beyond the time that the ﬁrst auto-phosphorylation occurs
as there are at least seven auto-phosphorylation sites. In vivo,
a protein substrate has to compete with the “uncharged” auto-
phosphorylation sites for the catalytic center. In addition, available
auto-phosphorylation sites can be replenished by phosphatases
(Koh et al., 2002). The following questions remain unanswered:
is auto-phosphorylation essential for kinase activities towards
an exogenous protein substrate? Is there a site that becomes
auto-phosphorylated earlier than any other sites? Is auto-
phosphorylation sequential or random or regulated by Pak1
partners? Do different combinations of auto-phosphorylations
lead to different modes of activation or functional effects? Are
there mutations in Pak1 that can bring about the same conforma-
tional changes as well as the same effects on downstream effectors
induced by auto-phosphorylation?
Since its discovery in 1994, many phosphoproteins have been
assigned as Pak substrates (Bokoch, 2003). The identiﬁed proteins
regulate a wide variety of cellular processes including proliferation
(King et al., 1998; Beeser et al., 2005; Jin et al., 2005), apoptosis
(Schurmann et al., 2000), generation of reactive oxygen species
(Knaus et al., 1995), contractility and cell remodeling (Edwards
et al., 1999; Sanders et al., 1999), etc. Obviously, caution must
be taken to extend the results from in vitro conditions to the in
vivo state. In addition, the use of GST-fusion proteins (GST-Pak1)
may interfere with auto-phosphorylation, dimerization and sub-
strate speciﬁcity of Pak1. These issues emphasize the importance of
employing different approaches with the objective to understand
Pak1 catalytic activity in mammalian cells and animal models.
REGULATION OF CYTOSKELETAL RE-ORGANIZATION AND
ENDOTHELIAL BARRIER FUNCTION
Induction of cytoskeletal re-organization by Pak1 has been
demonstrated bymicroinjection of plasmids coding different Pak1
mutants in mammalian cells. Pak1 was made constitutively active
by the pseudo-phosphorylation mutant, T423E, in the activation
loop, by mutations in dimerization domains, by single amino
acid change in PBD and by truncation of Pak1 N-terminal region
including the AID. The gain of function mutations induce loss of
stress ﬁbers and enhanced formation of lamellipodia and ﬁlapo-
dia in mammalian cells (Manser et al., 1997; Sells et al., 1997;
Frost et al., 1998). How does Pak1 activation induce collapse of
F-actin (ﬁlamentous actin)? The answer to this question may
reside in proteins that regulate actomyosin polymerization and
assembly. Phosphorylation of MLC20 enhances the activity of
myosin II and likely assembly of actomyosin in mammalian cells
(Smith et al., 1983; Kamm and Stull, 2001). A more pertinent
protein that regulates F-actin dynamics is actin depolymeriza-
tion factor, ADF/coﬁlin (Bamburg, 1999). Phosphorylation of
ADF/coﬁlin at Ser 3 prevents its binding to a complex at the barbed
end of F-actin and releases its inhibitory effect on formation or
prolongation of F-actin. ADF/coﬁlin also has capacity to sever pre-
existing F-actin (Bamburg et al., 1999). The question arises: How
does Pak1 affect phosphorylation and activities of MLC20 and
ADF/coﬁlin?
The advantage of studying protein phosphorylation using
recombinant viruses lies in their property of transfecting and
expressing a recombinant protein in nearly 100% of cultured
mammalian cells while the viral gene expression is repressed
(Kozarsky and Wilson, 1993; Ke et al., 2004). Therefore, change
in protein phosphorylation caused by an enhanced or reduced
upstream signal can be better detected. Employing a recombinant
Semliki Forest virus that expressed constitutively active Pak1, it
was observed that phosphorylation of MLC20 in BHK-21 cells was
reduced (Sanders et al., 1999).
Recombinant adenovirus is an excellent example of nanotech-
nology being used to study signal molecules in different disease
models. Recombinant adenoviruses have a diameter of 70–90 nm.
They transfect most of mammalian cells at high efﬁciency both
in vitro and in vivo and expressed exogenous proteins ranged from
a few kD to 200 kD (Kennedy and Parks, 2009). The viral genome
exists in mammalian cells in an episomal state without risk of
causing insertional mutagenesis. The puriﬁed recombinant ade-
noviruses can be stored over years at −80◦C and theoretically,
1 ml of viral preparation has the capacity to infect as many as
109 mammalian cells at a multiplicity of infection (MOI) of 10
and above (Kozarsky and Wilson, 1993). In addition, the tagged
recombinant proteins can be monitored easily in situ and puri-
ﬁed from different types of mammalian cells, sometimes along
with their binding partners, by afﬁnity chromatography (Ke et al.,
2004). Elucidation of mechanisms in the study of protein kinase
A (PKA) and Pak1 activities in endothelial cell barrier dysfunction
and cell signaling in cardiomyocytes represents a successful appli-
cation of recombinant adenoviruses (Ke et al., 2004, 2007b; Lum
et al., 1999).
Endothelial monolayer forms a restrictive barrier that reg-
ulates communication between blood and tissues. The barrier
dysfunction occurs during many pathological conditions includ-
ing lung injury, ischemic heart diseases, chronic kidney diseases
and inﬂammation. Signaling molecules that affect endothelial
barrier function primarily work through one or more of the
three major regulatory mechanisms: tight/gap junctions, focal
adhesions and internal contractility (Lum and Malik, 1994). All
of these can be measured with an instrument called electric
cell-substrate impedance sensor (ECIS), which monitors trans-
endothelial electrical resistance that dramatically decreases when
endothelial cells are challenged by inﬂammation mediators such
as histamine and thrombin (Tiruppathi et al., 1992). The dynamic
curve produced by ECIS is shaped and modiﬁed by alteration
of cell–cell connection, cell–matrix interaction and actomyosin
activities. Protein phosphorylation plays an important role in
control of barrier function. For instance, multiple lines of investi-
gation have demonstrated that inhibition of MLCK and reduction
in MLC20 phosphorylation protect endothelial barrier integrity
(Dudek and Garcia, 2001). Therefore, it is interesting to know
how Pak1 regulates endothelial barrier dysfunction.
In endothelial cells, expression of the active Pak1 via recom-
binant adenovirus induces dephosphorylation of MLC20 and
inhibits thrombin stimulated barrier dysfunction (Ke et al., 2007b;
Figure 2). These observations appear to shed light on molecular
mechanisms responsible for Pak1 initiated cytoskeletal reorga-
nization inasmuch as phosphorylation of MLC20 may regulate
assembly of myosin II as well as myosin II activities (Beeser
et al., 2005). It was ﬁrst concluded that Pak1 induces dephos-
phorylation of MLC20 through phosphorylation and inhibition of
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FIGURE 2 | Endothelial barrier dysfunction is inhibited by expression
of constitutively active Pak1 mediated by recombinant adenovirus
(AdPak1) through dephosphorylation of MLC20. (A) Pak1 reduces
thrombin mediated decrease of trans-endothelial electrical resistance as
measured by ECIS; (B) Bar graph representation of results in A indicates that
resistance drop induced by thrombin is rescued by Pak1; (C) Pak1 reduces
phosphorylation of myosin regulatory light chain (MLC20) at both threonine 18
and serine19 through activation of PP2A. M, phosphorylated MLC20 as
marker; Ctrl, control; AdPak1, recombinant adenovirus expressing
constitutively active Pak1.
MLCK because GST-Pak1 phosphorylated MLCK puriﬁed from
smooth muscle cells and inhibited its activities in vitro (Sanders
et al., 1999). However, further studies with constitutively active
Pak1(caPak1) without the GST tag failed to phosphorylate MLCK
of the same source in vitro. In addition, the caPak1 did not
reduce phosphorylation of MLC20 in smooth muscle cells (Ke
et al., 2007b). In smooth muscle cells, Pak1 induces formation of
the podosome, a structure similar to ﬁlapodia (Webb et al., 2005).
Therefore, dephosphorylation ofMLC20 may not account for Pak1
induced cell remodeling.
Neuronal growth cone remodeling is regulated by Rho fam-
ily small G proteins and their downstream effectors. Cdc42/Rac1
and Rho A antagonize each other in regulation of the dynamics of
neurite outgrowth (Jalink et al., 1994; Kozma et al., 1997; Brown
et al., 2000). The opposite activities are recapitulated by Pak1 and
Rock (Daniels et al., 1998; Hirose et al., 1998; Tudor et al., 2005;
Boda et al., 2006). In mouse model with ablation of both Pak1
and Pak3 expression, there is an impaired postnatal brain growth
associated with reduction in dendrites and axons (Huang et al.,
2011). Pak1 and Pak3 may compensate with each other in guid-
ing neuronal morphogenesis (Boda et al., 2008). ADF/coﬁlin is
involved in neurite outgrowth, regulated by Lim kinase and several
protein phosphatases, PP1, PP2A and PP2B (Meberg et al., 1998;
Ambach et al., 2000; Samstag and Nebl, 2003). Phosphorylation
of ADF/coﬁlin by Lim kinase at serine 3 inactivates its F-actin
depolymerization activity accompanied by collapse of the growth
cone (Aizawa et al., 2001). Inhibition of growth cone formation
was also observed when the phosphatase inhibitor okadaic acid
was applied in PC12 cells (Chiou and Westhead, 1992). Stud-
ies with ADF/coﬁlin mutants indicate that ADF activity is critical
for promoting neurite extension.While the non-phosphorylatable
form of ADF/coﬁlin induces neurite outgrowth, the pseudo-
phosphorylated mutant does not promote the structure (Meberg
and Bamburg, 2000), which suggests that dephosphorylation
of ADF/coﬁlin is essential for neurite outgrowth (Meberg et al.,
1998). Inhibition of PP1 by Rho A/Rock, which leads to inac-
tivation of ADF/coﬁlin, is responsible for collapse of the same
structure (Hirose et al., 1998; Bito et al., 2000; Lingor et al., 2007).
Increased ADF/coﬁlin activity may initiate accelerated turn-over
of F-actin required for establishment of a new structure rich in
F-actin (Gallo and Letourneau, 2004; Flynn et al., 2012). Recent
studies have demonstrated that Pak1 is important in regulation
of t-tubular networks in ventricular myocytes (Desantiago et al.,
2013). T-tubules are deep invaginations of the sarcolemma, bring-
ing the extracellular space to the interior regions of the cell for
insuring efﬁcient excitation-contraction coupling. It is of interest
to knowwhether there is a commonmechanism regulating plasma
membrane protrusion and invagination involving Pak1.
ACTIVATION OF PP2A BY Pak1 THROUGH SCAFFOLDING
An important aspect of Pak1 signaling is its interactions with
PP2A. PP2A is a multi-faceted, multi-task phosphatase respon-
sible for dephosphorylation of many different phosphoproteins in
the heart and in other mammalian cells (Janssens and Goris, 2001;
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Ke et al., 2008). It consists of a catalytic subunit (C) with two
isoforms, a scaffolding subunit (A) also with two isoforms and
a regulatory subunit (B) with at least 18 isoforms. Thus a large
number of variations can be formed by different combination of
three subunits that associates with distinct protein substrates and
carrying out phosphatase activity on these targets regulated in both
temporal and spatial manner. At the C terminus of the C subunit,
post-translational modiﬁcations including methylation at L309
and tyrosine phosphorylation at Y307 regulate PP2A transloca-
tion, substrate speciﬁcity and phosphatase activity (Janssens et al.,
2008). Inhibition of PP2A by okadaic acid induces tumorigene-
sis (Haystead et al., 1989) and increase pacemaker activity in SA
(sino-atrial) node (Kondo et al., 1990).
Association of Pak1 with PP2A was ﬁrst demonstrated in rat
brain. Cross-linking of PP2Ac (the catalytic subunit of PP2A)
with its partners in brain extract shifts the Pak1 signal to a higher
molecular weight position in SDS PAGE (Westphal et al., 1999).
Association of Pak1 with PP2A is not limited to brain tissue. In
the heart, both endogenous and constitutively active Pak1 are
binding partners for PP2A and expression of the constitutively
active Pak1 induces PP2Ac dephosphorylation at Y307. In rat
ventricular myocytes, Pak1 activates PP2A and reduces phospho-
rylation on troponin I, myosin binding protein C, connexin 43
andmicrotubule-associated protein (MAP4; Ke et al., 2004; Cheng
et al., 2010, 2012; Ai et al., 2011). In SA nodal cells, active Pak1 and
PP2A demonstrate the same altered pattern of localization (Ke
et al., 2007a). Activation of PP2AbyPak1was also demonstrated in
endothelial cells andmast cells (Ke et al., 2007b; Staser et al., 2013).
While phosphorylation of ADF/coﬁlin promotes polymeriza-
tion of F-actin, MAP4 phosphorylation stimulates disruption of
the microtubule network in cardiomyocytes. A Pak1 induced rise
of phosphatase activity leads to increased formation of the micro-
tubule network accompanied by dephosphorylation of MAP4, a
tau-like protein (Cheng et al., 2010). An increase of polymerized
microtubules could be an indication of ventricular hypertrophy
(Tsutsui et al., 1993; Tagawa et al., 1996). On the other hand,
myocardial infarction (MI) is often associated with the disruption
of microtubule network (Iwai et al., 1990).
The constitutively active Pak1 variant co-puriﬁes with PP2A
from mammalian cell lines, but it does not phosphorylate the
PP2A in vitro (Ke et al., 2004). In addition, constitutively active
Pak1 does not phosphorylate PP2A isolated from a muscle source
in vitro. These results indicate that activation of PP2A may be
through a scaffolding mechanism (Ke et al., 2008; Figure 3). PP2A
dephosphorylates multiple targets and is involved in regulation
of cardiac excitation and contraction. Moreover in Pak1 knock-
out mice, phosphorylation of coﬁlin at serine-3 was elevated with
altered regulation of glucose homeostasis (Wang et al., 2011b).
ANTI-ADRENERGIC ACTIVITY OF Pak1 IN THE HEART
In cardiomyocytes, PKA phosphorylation is often reversed by
PP2A. Activation of Pak1/PP2A thus represents a novel molecular
mechanism that antagonizes β-adrenergic signaling in the heart.
Rhythmic and effective contraction and relaxation of myocardium
requires integration of electrical signals, Ca2+ transients and
myoﬁlament cross-bridge cycling, which are all subjected to reg-
ulation of protein kinases and phosphatases (Lei et al., 2007;
Sheehan et al., 2007; Ke et al., 2008). β-adrenergic signaling
pathways mediated by cAMP dependent protein kinase induce
increased phosphorylation of L-type Ca2+ channels and ryan-
odine receptors leading to enhanced Ca2+ inﬂow and Ca2+
induced Ca2+ release from sarcoplasmic reticulum (Kamp and
Hell, 2000; Ke et al., 2008); phosphorylation of troponin I at serine
23, 24 accompanied by accelerated cross-bridge detachment and
myocardial relaxation (Solaro et al., 2013); phosphorylation of
phospholamban, which renders faster SERCA2a Ca2+ reuptake
activity. PP2A usually removes phosphate groups from PKA tar-
gets at the same phosphorylation sites (Ke et al., 2008). In cultured
adult rat ventricular myocytes, expression of constitutively active
Pak1 induces dephosphorylation of cardiac troponin I, myosin
binding protein C and increased Ca2+ sensitivity of myoﬁlament
force development. In SA nodal cells, Pak1 inhibits isoproterenol
(ISO) induced increases of pacemaker activity through regulation
of activities of L-typeCa2+ anddelayed rectifying potassiumchan-
nels (Ke et al., 2007a). In mouse with complete ablation or cardiac
speciﬁc knock-out of Pak1, there is an accelerated progression to
FIGURE 3 | Activation of phosphatase PP2A by Pak1 scaffolding. Through a conformational change associated with Pak1 autophosphorylation, PP2A
undergoes auto-dephosphorylation with increased phosphatase activities. Pak1 remains in dimer form and associated with PP2A even after
auto-phoshporylation.
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hypertrophy in response to stresses induced by chronic treatment
with ISO or by transverse aortic constriction (TAC; Liu et al., 2011;
Taglieri et al., 2011).
There is also evidence that active Pak1 acts as antagonist of
angiotensin II signaling. In neonatal cardiomyocytes, mechani-
cal or hormone-induced hypertrophy can be blocked by type I
angiotensin II receptor antagonists (Yamazaki et al., 1996), and
checked by Rho inhibitors (Hoshijima et al., 1998) and inhibited
by expression of constitutively active Pak1 (Liu et al., 2011). Pak1
may also have a beneﬁcial role in improving cardiac functions dur-
ing endotoxemia by blocking a TNF signaling pathway involving
activation of another protein phosphatase mitogen-activated pro-
tein kinase phosphatase-1 (MKP-1; Zhang et al., 2012). On the
other hand, Pak1 may contribute to expression of inﬂammatory
markers on endothelium at atherosclerosis-susceptible regions of
arteries in vivo (Jhaveri et al., 2012). To conﬁrm and extend all the
above observations in larger animals and in humans, development
of potent and speciﬁc molecular tools targeting Pak1 activation
will be important and valuable.
IMPLICATION IN THERAPEUTICS AND DRUG DEVELOPMENT
Knowledge related to the extensivemolecular interactions between
the Pak1 monomers and the Pak1 kinase domain, which has the
capacity to interact with and phosphorylate multiple sequences in
the N-terminal half of the kinase, has provided great potential to
design peptides targeting Pak1 in vitro and in vivo. The peptide
sequences surrounding or close to auto-phosphorylation sites are
especially interesting inasmuch as all the auto-phosphorylation
sites along with the adjacent amino acids interact with the Pak1
kinase domain. Based on crystal structures, most of the interac-
tion of the N-terminal motifs with the Pak1 kinase domain occurs
in “trans” or through an inter-molecular mechanism between
two Pak1 monomers. A Pak1 interacting peptide has to compete
with the cognate or native peptide (the corresponding peptide
sequence inside the Pak1molecule) for the same binding region in
Pak1. This competition could dislocate the “native peptides” and
attenuate the Pak1–Pak1 interaction. Thus, interruption of Pak1
homodimer and attenuation of auto-inhibition may occur. PRR-
1 and PID are bioactive peptides interacting with Pak1 (Zenke
et al., 1999; Ke and Solaro, 2008), and both containing auto-
phosphorylatable amino acids. PRR-1 is derived from the Pak1
ﬁrst proline-rich repeat that promotes Pak1 translocation from
the plasma membrane to cytosolic fractions (Kiosses et al., 2002).
PRR-1 reduces phosphorylation of myosin regulatory light chain
in endothelial cells (Stockton et al., 2004). The same effect was
produced by constitutively active Pak1 in the same cell type
(Ke et al., 2007b). PID is derived from Pak1 inhibitory domain,
which lies immediately downstream and even overlaps with PBD.
Although it was regarded as a Pak1 inhibitor, the peptide actually
reduced paxillin density at the cell periphery (Delorme-Walker
et al., 2011). The same phenotype was observed in mammalian
cells expressing constitutively active Pak1 (Manser et al., 1997),
Pak18 is a peptide derived from the region that interacts with Pix.
The Pix interacting region must also be able to interact with the
Pak1 kinase domain because it contains two auto-phosphorylation
sites. Interestingly, the peptide reduced phosphorylation ofMLC20
(Santiago-Medina et al., 2013), a functional effects produced by
expression of constitutively active Pak1 (Sanders et al., 1999; Ke
et al., 2007b).
Studies of Pak1 mutants indicate that mutations of Pak1 often
lead to gain of Pak1 activities. For example, mutation of amino
acids in Pak1 dimerization region H81 and H86 attenuate Pak1
dimerization and increases auto-phosphorylation and Pak1 activ-
ity on cytoskeletal reorganization. Change of an amino acid in
PBD domain, L107F has an even stronger effect in activating Pak1.
Similarly, switch of serine and threonine at auto-phosphorylation
sites to acidic amino acids mimicking phosphorylation increases
Pak1 activity. Truncation of amino acids at the Pak1 N-terminal
region (Frost et al., 1998) and cleavage of Pak2 increases auto-
phosphorylation (Walter et al., 1998) and provide a means of gain
of Pak1 activities. In frog embryo, microinjection of protease
activated Pak2 signiﬁcantly inhibited cell division (Rooney et al.,
1996). Pak1 and Pak3 are highly homologous to each other. Muta-
tions of amino acids R67C and A365E in Pak3 located distantly
from each other result in the same genetic defects, mental retarda-
tion inhumans (Bienvenu et al.,2000; Gedeon et al.,2003). Human
Pak3MRX30mutationwith premature termination of Pak3 trans-
lation induced an increase of ﬁlopodia-like protrusions and long
spines in pyramidal neurons (Boda et al., 2004). Whether these
mutations could be traced to the same enzymatic activity change
or change in signaling activity requires further investigation.
As a key regulatory molecule crucial for multiple physiological
processes, it is not surprising that Pak1 is regulated at multiple
levels by diverse mechanisms (Figure 4). Activation of Pak1 by
low molecular weight molecules exists in nature, and it is likely
that some of those may not have been discovered yet. Pak1 is
directly activated by sphingosine in vitro and in vivo characterized
by an increase of auto-phosphorylation, bypassing upstream pro-
tein signals (Gedeon et al., 2003; Jhaveri et al., 2012). Sphingosine
is enriched in lipid rafts and exists in all mammalian cells regulat-
ing diverse cellular processes including pacemaker activities when
converted to sphingosine phosphate (Boda et al., 2004; Strader
et al., 2011). C2 and C6 ceramides are PP2A activators and struc-
turally similar to sphingosine. They both activate Pak1 in vitro
(Ke and Solaro, 2008). A sphingosine analog, FTY720, was derived
from myriocin (ISP-1), a metabolite from fungus Isaria sinclairii,
a Chinese traditional medicine with a variety of therapeutic appli-
cations (Adachi and Chiba, 2008; Strader et al., 2011). In humans,
FTY720 induces bradycardia and antagonizes the chronotropy of
ISO (Kovarik et al., 2008a,b). In ex vivo rat heart, FTY720 normal-
izes arrhythmias triggered by enhanced β-adrenergic stimulation
through Pak1 activation (Brinkmann et al., 2002). A recent study
also indicates that FTY720 effectively prevents dendrite loss in
a mouse model of experimental autoimmune encephalomyelitis
(Rossi et al., 2012).
FTY720 is converted to FTY720-phosphate by sphingosine
kinase and then binds to sphingosine-1 phosphate receptors
(Brinkmann et al., 2002), which has been considered as the major
signaling pathways in vivo. However, in endothelial cells, inhibi-
tion of sphingosine-1 phosphate receptors did not abolish FTY720
induced enhancement of barrier integrity (Dudek et al., 2007),
suggesting FTY720 protects endothelial barrier function through a
different pathway. A similar observationwasmade in the heart that
FTY720 protects an ischemic heart by post-conditioning similar
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FIGURE 4 | Scaffolding of Pak1-PP2A induces different functional changes in endothelial, cardiac and other mammalian cells. It is also a novel
anti-adrenergic mechanism in the heart. The Pak1-PP2A scaffolding can be enhanced by small molecular weight compounds such as FTY720. See text for
further discussion.
to sphingosine, but independent of either sphingosine kinase or
S1P receptors (Vessey et al., 2013). In ex vivo hearts, FTY720 treat-
ment induces an increase in Pak1 auto-phosphorylation (Egom
et al., 2010). The ex vivo heart responds to FTY720 instantly,
which may suggest that Pak1 is directly activated by FTY720
(Egom et al., 2010). Identiﬁcation of a more speciﬁc agonist that
turns on Pak1 activities in vivo will not only have application to
further deﬁne Pak1 function in vivo, but also may serve as a novel
therapeutic approach for cardiovascular diseases. FTY720 acti-
vates PP2A and inhibits tumor cell growth and tumorigenesis (Liu
et al., 2008; Yang et al., 2012; Saddoughi et al., 2013). In mice TAC
induced cardiac hypertrophy can be both inhibited and reversed
by FTY720. The anti-hypertrophic effects are abolished in mouse
models with cardiac speciﬁc knock-out of Pak1 (Liu et al., 2011).
Although some efforts have beenmade to understand themolecu-
lar mechanism whereby Pak1 is turned on by sphingosine (Zenke
et al., 1999; Chong et al., 2001), activation of Pak1 by compounds is
an under-explored ﬁeld. Because an autoinhibitory conﬁguration
of Pak1 is maintained through multiple sequences throughout the
whole molecule, it will not be surprising that Pak1 activation or
release of Pak1 auto-inhibition can be realized by molecules that
are structurally very different.
CONCLUSION
Employment of scaffolding in signal transduction by Pak1
challenges the conventional understanding of a protein kinase.
Some protein kinases other than Pak family members may also
use the same signaling mechanism, but are not yet uncovered.
Better understanding of scaffolding of Pak1 not only provides
novel insights and enriches our knowledge on diverse modes
of signal transduction, but also serves as guide for drug design
and therapeutics targeting at Pak1. Substantial efforts have
been made to develop inhibitors for Paks. Highly selective ago-
nists for Pak1 may be equally important. The unique structure
and catalytic activity of Pak1 has provided great potential for
design and development of Pak1 activators through disruption
of Pak1 auto-inhibition. These molecular tools should be valu-
able in further exploring Pak1 function in vivo and serve as
drug candidates for novel therapeutics of major cardiovascular
diseases.
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